Hytn Innovations
The company works within the cannabis CPG market by producing nano-emulsions, beverages, edibles, dry flower processing and non-solid extracts.
The company processes GMP-certified cannabis and manufactures GMP-certified psilocybin mushrooms, fabricates live resin API, bulk dry flower API, bulk dry psilocybin mushroom API, bulk solventless extraction API.
The company cultivates psilocybin mushrooms and plans to produce a wide arrange of API’s through its Dealer’s License given by Health Canada.
The company transforms Canadian-grown cannabis into final medical products that meet GMP-standards and aims to unlock global markets for established cannabis brands by leveraging the company’s regulatory compliance, supply chain capabilities and quality management system.
The company is aiming to achieve cGMP accreditation in both Canada and Australia. Until this has been achieved, the company is concentrating on producing psilocybin extracts, expanding its cannabis product lines as well as refining approved substances.
OWNERSHIP:
Elevation Technology is the company’s proprietary clear, odorless emulsions featuring nano-sized droplets, increasing absorption and enhanced bioavailability that deliver rapid, predictable and consistent effects. Elevation Technology plays a crucial role in generating a novel chemical entity by creating unique and stable nano-emulsions that improve the bioavailability and efficacy of active ingredients. This proprietary technology allows for the precise formulation of cannabinoids and other compounds into new, patentable forms, effectively transforming them into NCE’s.
Products:
The company produces calorie-free cannabis-infused beverages and gummies. With the elevation technology, HYTN can create a clear, odorless emulsion with evenly distributed THC that provides a rapid onset where most people report a predictable peak within 30 minutes.
FACILITIES:
2475 sq ft of licensed storage capacity.
DRUG PROGRAMS TARGET:
SUBSTANCE FOCUS: THC, Psilocybin,
NEWS & PARTNERSHIPS:
2021
The company signed a definitive agreement with Emerald Health Therapeutics under which Emerald will co-launch, sell and distribute HYTN’s proprietary new sparkling cannabis beverages, which employ fast-acting Elevation Technology across Canada. Emerald will receive a double-digit percentage fee on total gross sales revenue, less excise tax.
2022
The company successfully developed, exported and launched its cannabis nano-emulsions featuring HYTN’s proprietary Elevation Technology in the Australian cannabis medical market through a manufacturing and sales agreement with Promethean BioPharma. The company also started selling cannabis flower to serve the Australian medical cannabis market under the Promethean BioPharma brand.
The company signed a sales, distribution and marketing agreement to sell its products through Rose LifeScience in Quebec in exchange for a commission for their services.
The company started accepting cannabis-infused beverage orders directly from provincially and territorially authorized retailers as it was preparing to transition away from its partnership with Emerald Health Therapeutics, now also accepting orders from new markets including Nova Scotia and Yukon.
2023
The company entered into a manufacturing agreement with Tricanna Industries for its pre-rolls with a percentage of the net sales price of all the revenue from orders of pre-rolled cannabis products given to the company.
The company was awarded a license to possess, produce, assemble, transport and sell psilocybin by Health Canada.
2024
The company received Australia’s TGA GMP-certification for its Kelowna, Canada production facility.
The company acquired Prism Labs to strengthen the company’s capabilities in the manufacture of psychedelic compounds, especially boosting the yield of tryptamine in psychedelic mushrooms. It also gives the company HYTN exclusive access to Prism’s intellectual property, including a significant license from Lux Sit Systems.
The company noted that its GMP-cannabis products had a shelf life of 6 months for items in bags and 1 year for those in jars.
The company’s Nano Shot was expanded into the British Columbia and Alberta markets after its success in Ontario.
The company signed a 2-year partnership agreement with SNDL where HYTN helps process SNDL cannabis products destined for international markets.
The company partnered with 4C LABS where HYTN will act as a producer, packager and exporter of pharmaceutical quality cannabis products that 4C LABS can acquire, import and distribute in the UK. HYTN plans to manufacture new products for 4C LABS while also serving as a co-manufacturing center for the production of existing products currently produced at various locations, with the aim of enhancing operational efficiency for both companies. The initial focus of the partnership is to supply products to the UK market, however, both companies see opportunities in Germany and Australia.
2025
The company received new import permits from the UK Home Office and corresponding export permits from Health Canada, allowing the company to fulfill international orders for over 400 kilograms of GMP-certified cannabis products.
The company entered into a collaboration agreement with SNDL to jointly develop GMP-compliant vape cartridges for global markets. HYTN will utilize its GMP-certified facility and quality system expertise to implement the necessary processes, while SNDL will provide the specialized equipment, cannabis consumables, and capital required to meet stringent international regulatory standards. While the partnership focuses on achieving the milestone of processing three commercial batches, there is no requirement for exclusivity, sales volume, or pricing, with both parties open to exploring a formal commercial manufacturing agreement upon successful completion of the development phase.
The company launched a Good Manufacturing Practice Stability Program and initiated the validation of its cannabis vape cartridges to meet the stringent regulatory requirements of international medical markets, including Germany, the UK, and Australia. In collaboration with a GMP-licensed laboratory, the company is conducting stability testing, initially targeting a six-month statement, with plans for 12-month extensions, to ensure long-term product viability. The company also finalized the selection of its cartridge manufacturer and commenced comprehensive qualification and process validation for its 1g ceramic coil vaporizer cartridges. To support this expanded product portfolio, which will eventually include live resin and live rosin offerings, the company submitted an amendment to its Health Canada licensing framework to include cannabis oil as an approved dosage form.
The company entered into a comprehensive collaboration with A1 Cannabis in order to enhance its operational efficiency and to expand the presence of both in the cannabis beverage market. The collaboration is for a 3-year term and includes a manufacturing as well as a consulting agreement. The collaboration also includes a letter of understanding which ties the agreements together. The agreements will allow for A1 to transition its full cannabis product portfolio from Tilray Brands to HYTN. A1 will offer sales management services and HYTN will provide the facilities, licenses and qualifications required for product development within its licensed infrastructure and A1’s CEO Cole Miller from A1 will oversee HYTN’s domestic product sales forecasting, product development, and sales management for its 5- and 10-milligram Sparkling Beverages as well as its 100-milligram Nano Shots in order to optimize market reach and revenue growth which will result in a revenue-sharing agreement for all A1/Summit-branded products.
HYTN will register, manufacture, collect revenues and sell A1 products under its own licenses and approvals and A1 will keep the rights to the A1 and Summit brands, product formulations and related IP.
The company received digital Good Manufacturing Practices certificates from Health Canada for its Kelowna-based manufacturing facility, acknowledging its compliance for the United States, Bermuda, and Israel.
The company entered into strategic supply agreements and completed vendor qualification with 2 cannabis cultivators under its GMP system, qualifying at least 4000 KG for the German market. Klonetics Plant Science is 1 of the companies and the other wished to remain undisclosed.
The company received an initial purchase order and import permit for 1,000 one-gram, GMP-compliant live resin vape cartridges. The order is from SNDL and is to be manufactured at its Kelowna facility and exported to the UK under its Drug Establishment Licence (DEL).
2026
The company received an expanded Health Canada Drug Establishment License for its Kelowna facility after a successful GMP inspection. The facility is now authorized to fabricate, package, and label non-sterile APIs in both solid and non-solid forms and adds pharmaceutical oil as an authorized finished dosage form.
The company manufactured and exported its first commercial batch of GMP-finished cannabis vape cartridges to Australia’s regulated medical cannabis market with a shipment of 1,000 units of 1-gram live resin vape cartridges.
The company launched its proprietary Hermetic Autogenous Remediation (HARd) as a commercial service for dried cannabis flower. Developed within the company’s GMP quality systems, the process is designed to reduce microbial burden to meet stringent European Pharmacopoeia standards for inhalation while preserving the flower’s physical and chemical integrity without the use of radiation, heat, or chemicals. The company has already successfully utilized HARd for a commercial product release in Germany, and it now intends to offer the process as a service to other domestic and international partners, particularly those seeking non-irradiation remediation pathways for premium cannabis products.
The company announced a proposal to spin out its internal peptide drug development business into a new, dedicated entity which will focus on advancing a BPC-157 drug candidate for the treatment of refractory ligament disorders, leveraging the existing GMP-compliant infrastructure, regulatory frameworks and clinical-support systems incubated within HYTN. The proposed transaction includes a concurrent CAD $1 million private placement to fund clinical development and is intended to support a future public listing on the Canadian Securities Exchange.